Eliquis

Overview

apixaban

factor Xa inhibitor

• CYP3A4 substrate
• P-gp substrate
• anticoagulant

Contraindicated

• defibrotide
Eliquis (apixaban)

+

defibrotide

1 interaction

Contraindicated

apixaban + defibrotide

contraindicated: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• mifepristone
Eliquis (apixaban)

+

mifepristone

1 interaction

Contraindicated

apixaban + mifepristone

contraindicated if pregnancy termination use; monitor bleeding s/sx if daily mifepristone use; decr. apixaban dose by 50% during and x14 days after daily mifepristone use; avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of severe or prolonged vaginal bleeding or other bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

Avoid/Use Alternative

• abrocitinib
Eliquis (apixaban)

+

abrocitinib

1 interaction

Avoid/Use Alternative

apixaban + abrocitinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• adagrasib
Eliquis (apixaban)

+

adagrasib

1 interaction

Avoid/Use Alternative

apixaban + adagrasib

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• amiodarone
Eliquis (apixaban)

+

amiodarone

1 interaction

Avoid/Use Alternative

apixaban + amiodarone

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• apalutamide
Eliquis (apixaban)

+

apalutamide

1 interaction

Avoid/Use Alternative

apixaban + apalutamide

avoid combo: combo may decr. apixaban levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• asciminib
Eliquis (apixaban)

+

asciminib

1 interaction

Avoid/Use Alternative

apixaban + asciminib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• atazanavir
Eliquis (apixaban)

+

atazanavir

1 interaction

Avoid/Use Alternative

apixaban + atazanavir

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• azithromycin
Eliquis (apixaban)

+

azithromycin

1 interaction

Avoid/Use Alternative

apixaban + azithromycin

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• belumosudil
Eliquis (apixaban)

+

belumosudil

1 interaction

Avoid/Use Alternative

apixaban + belumosudil

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• bisoprolol
Eliquis (apixaban)

+

bisoprolol

1 interaction

Avoid/Use Alternative

apixaban + bisoprolol

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• brigatinib
Eliquis (apixaban)

+

brigatinib

1 interaction

Avoid/Use Alternative

apixaban + brigatinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• butalbital
Eliquis (apixaban)

+

butalbital

1 interaction

Avoid/Use Alternative

apixaban + butalbital

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. apixaban levels, efficacy (hepatic metab. induced)

• canagliflozin
Eliquis (apixaban)

+

canagliflozin

1 interaction

Avoid/Use Alternative

apixaban + canagliflozin

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• cannabidiol
Eliquis (apixaban)

+

cannabidiol

1 interaction

Avoid/Use Alternative

apixaban + cannabidiol

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• caplacizumab
Eliquis (apixaban)

+

caplacizumab

1 interaction

Avoid/Use Alternative

apixaban + caplacizumab

use alternative or monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• capmatinib
Eliquis (apixaban)

+

capmatinib

1 interaction

Avoid/Use Alternative

apixaban + capmatinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• captopril
Eliquis (apixaban)

+

captopril

1 interaction

Avoid/Use Alternative

apixaban + captopril

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• carbamazepine
Eliquis (apixaban)

+

carbamazepine

1 interaction

Avoid/Use Alternative

apixaban + carbamazepine

avoid combo: combo may decr. apixaban levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• carvedilol
Eliquis (apixaban)

+

carvedilol

1 interaction

Avoid/Use Alternative

apixaban + carvedilol

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• ceritinib
Eliquis (apixaban)

+

ceritinib

1 interaction

Avoid/Use Alternative

apixaban + ceritinib

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• chloramphenicol
Eliquis (apixaban)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

apixaban + chloramphenicol

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• cimetidine
Eliquis (apixaban)

+

cimetidine

1 interaction

Avoid/Use Alternative

apixaban + cimetidine

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• cobicistat
Eliquis (apixaban)

+

cobicistat

1 interaction

Avoid/Use Alternative

apixaban + cobicistat

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• collagenase clostridium histolyticum
Eliquis (apixaban)

+

collagenase clostridium histolyticum

1 interaction

Avoid/Use Alternative

apixaban + collagenase clostridium histolyticum

DUPUYTREN or PEYRONIE: avoid combo w/in 7 days of apixaban use; CELLULITE: monitor injection site bleeding s/sx: combo may incr. risk of localized bleeding, incl. severe (additive effects)

• danicopan
Eliquis (apixaban)

+

danicopan

1 interaction

Avoid/Use Alternative

apixaban + danicopan

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• danshen
Eliquis (apixaban)

+

danshen

1 interaction

Avoid/Use Alternative

apixaban + danshen

avoid combo if also combined w/ strong CYP3A4 inducer; otherwise, monitor bleeding s/sx: combo may decr. apixaban levels, efficacy; may incr. risk of bleeding, incl. life-threatening (P-gp-mediated transport induced; additive effects)

• daridorexant
Eliquis (apixaban)

+

daridorexant

1 interaction

Avoid/Use Alternative

apixaban + daridorexant

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• diosmin
Eliquis (apixaban)

+

diosmin

1 interaction

Avoid/Use Alternative

apixaban + diosmin

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects)

• edoxaban
Eliquis (apixaban)

+

edoxaban

1 interaction

Avoid/Use Alternative

apixaban + edoxaban

use alternative or monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• elacestrant
Eliquis (apixaban)

+

elacestrant

1 interaction

Avoid/Use Alternative

apixaban + elacestrant

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• elexacaftor/tezacaftor/ivacaftor
Eliquis (apixaban)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

apixaban + elexacaftor/ tezacaftor/ ivacaftor

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• eliglustat
Eliquis (apixaban)

+

eliglustat

1 interaction

Avoid/Use Alternative

apixaban + eliglustat

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• enasidenib
Eliquis (apixaban)

+

enasidenib

1 interaction

Avoid/Use Alternative

apixaban + enasidenib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• encorafenib
Eliquis (apixaban)

+

encorafenib

1 interaction

Avoid/Use Alternative

apixaban + encorafenib

avoid combo if also combined w/ P-gp inducer; otherwise, monitor bleeding s/sx: combo may decr. apixaban levels, efficacy; may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• enoxaparin
Eliquis (apixaban)

+

enoxaparin

1 interaction

Avoid/Use Alternative

apixaban + enoxaparin

use alternative or monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• entrectinib
Eliquis (apixaban)

+

entrectinib

1 interaction

Avoid/Use Alternative

apixaban + entrectinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• enzalutamide
Eliquis (apixaban)

+

enzalutamide

1 interaction

Avoid/Use Alternative

apixaban + enzalutamide

consider alternative: combo may incr. or decr. apixaban levels, incr. risk of bleeding, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metab. induced)

• erdafitinib
Eliquis (apixaban)

+

erdafitinib

1 interaction

Avoid/Use Alternative

apixaban + erdafitinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose; separate admin. by at least 6h: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• felodipine
Eliquis (apixaban)

+

felodipine

1 interaction

Avoid/Use Alternative

apixaban + felodipine

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• flibanserin
Eliquis (apixaban)

+

flibanserin

1 interaction

Avoid/Use Alternative

apixaban + flibanserin

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• fluvoxamine
Eliquis (apixaban)

+

fluvoxamine

1 interaction

Avoid/Use Alternative

apixaban + fluvoxamine

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• fondaparinux
Eliquis (apixaban)

+

fondaparinux

1 interaction

Avoid/Use Alternative

apixaban + fondaparinux

use alternative or monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• fosphenytoin
Eliquis (apixaban)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

apixaban + fosphenytoin

avoid combo: combo may decr. apixaban levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• fostamatinib
Eliquis (apixaban)

+

fostamatinib

1 interaction

Avoid/Use Alternative

apixaban + fostamatinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• futibatinib
Eliquis (apixaban)

+

futibatinib

1 interaction

Avoid/Use Alternative

apixaban + futibatinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• gilteritinib
Eliquis (apixaban)

+

gilteritinib

1 interaction

Avoid/Use Alternative

apixaban + gilteritinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• ginkgo
Eliquis (apixaban)

+

ginkgo

1 interaction

Avoid/Use Alternative

apixaban + ginkgo

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects)

• glecaprevir
Eliquis (apixaban)

+

glecaprevir

1 interaction

Avoid/Use Alternative

apixaban + glecaprevir

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• ibritumomab tiuxetan
Eliquis (apixaban)

+

ibritumomab tiuxetan

1 interaction

Avoid/Use Alternative

apixaban + ibritumomab tiuxetan

use alternative or monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ibrutinib
Eliquis (apixaban)

+

ibrutinib

1 interaction

Avoid/Use Alternative

apixaban + ibrutinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding (incl. life-threatening), other adverse effects (gut P-gp-mediated transport inhibited, additive effects)

• idelalisib
Eliquis (apixaban)

+

idelalisib

1 interaction

Avoid/Use Alternative

apixaban + idelalisib

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• indomethacin
Eliquis (apixaban)

+

indomethacin

1 interaction

Avoid/Use Alternative

apixaban + indomethacin

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects)

• istradefylline
Eliquis (apixaban)

+

istradefylline

1 interaction

Avoid/Use Alternative

apixaban + istradefylline

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• itraconazole
Eliquis (apixaban)

+

itraconazole

1 interaction

Avoid/Use Alternative

apixaban + itraconazole

avoid combo during and x2wk after itraconazole tx: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• ivacaftor
Eliquis (apixaban)

+

ivacaftor

1 interaction

Avoid/Use Alternative

apixaban + ivacaftor

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• ivosidenib
Eliquis (apixaban)

+

ivosidenib

1 interaction

Avoid/Use Alternative

apixaban + ivosidenib

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. apixaban levels, efficacy (hepatic metab. induced)

• ketoconazole
Eliquis (apixaban)

+

ketoconazole

1 interaction

Avoid/Use Alternative

apixaban + ketoconazole

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• lapatinib
Eliquis (apixaban)

+

lapatinib

1 interaction

Avoid/Use Alternative

apixaban + lapatinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• lasmiditan
Eliquis (apixaban)

+

lasmiditan

1 interaction

Avoid/Use Alternative

apixaban + lasmiditan

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• ledipasvir
Eliquis (apixaban)

+

ledipasvir

1 interaction

Avoid/Use Alternative

apixaban + ledipasvir

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• lenacapavir
Eliquis (apixaban)

+

lenacapavir

1 interaction

Avoid/Use Alternative

apixaban + lenacapavir

monitor bleeding s/sx; consider decr. apixaban dose during and x9mo after lenacapavir tx: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• levacetylleucine
Eliquis (apixaban)

+

levacetylleucine

1 interaction

Avoid/Use Alternative

apixaban + levacetylleucine

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• levoketoconazole
Eliquis (apixaban)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

apixaban + levoketoconazole

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• lifileucel
Eliquis (apixaban)

+

lifileucel

1 interaction

Avoid/Use Alternative

apixaban + lifileucel

use alternative or monitor bleeding s/sx, especially if persistent or repeated thrombocytopenia: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• lomitapide
Eliquis (apixaban)

+

lomitapide

1 interaction

Avoid/Use Alternative

apixaban + lomitapide

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• lonafarnib
Eliquis (apixaban)

+

lonafarnib

1 interaction

Avoid/Use Alternative

apixaban + lonafarnib

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• lopinavir/ritonavir
Eliquis (apixaban)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

apixaban + lopinavir/ ritonavir

avoid combo: combo may incr. or decr. apixaban levels, incr. risk of bleeding, other adverse effects or decr. efficacy (hepatic metab. altered, P-gp-mediated transport inhibited)

• lumacaftor/ivacaftor
Eliquis (apixaban)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

apixaban + lumacaftor/ ivacaftor

avoid combo: combo may incr. or decr. apixaban levels, incr. risk of bleeding, other adverse effects or decr. efficacy (hepatic metab. induced, P-gp-mediated transport possibly altered)

• maribavir
Eliquis (apixaban)

+

maribavir

1 interaction

Avoid/Use Alternative

apixaban + maribavir

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• mavorixafor
Eliquis (apixaban)

+

mavorixafor

1 interaction

Avoid/Use Alternative

apixaban + mavorixafor

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• milk thistle
Eliquis (apixaban)

+

milk thistle

1 interaction

Avoid/Use Alternative

apixaban + milk thistle

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• mirabegron
Eliquis (apixaban)

+

mirabegron

1 interaction

Avoid/Use Alternative

apixaban + mirabegron

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• mitotane
Eliquis (apixaban)

+

mitotane

1 interaction

Avoid/Use Alternative

apixaban + mitotane

avoid combo if also combined w/ P-gp inducer; otherwise, monitor bleeding s/sx: combo may decr. apixaban levels, efficacy; may incr. risk of bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• naproxen
Eliquis (apixaban)

+

naproxen

1 interaction

Avoid/Use Alternative

apixaban + naproxen

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects)

• nefazodone
Eliquis (apixaban)

+

nefazodone

1 interaction

Avoid/Use Alternative

apixaban + nefazodone

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• nelfinavir
Eliquis (apixaban)

+

nelfinavir

1 interaction

Avoid/Use Alternative

apixaban + nelfinavir

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• neratinib
Eliquis (apixaban)

+

neratinib

1 interaction

Avoid/Use Alternative

apixaban + neratinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• netupitant
Eliquis (apixaban)

+

netupitant

1 interaction

Avoid/Use Alternative

apixaban + netupitant

use alternative or monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose during and x1wk after (fos)netupitant tx: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• nifedipine
Eliquis (apixaban)

+

nifedipine

1 interaction

Avoid/Use Alternative

apixaban + nifedipine

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• osimertinib
Eliquis (apixaban)

+

osimertinib

1 interaction

Avoid/Use Alternative

apixaban + osimertinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• paroxetine
Eliquis (apixaban)

+

paroxetine

1 interaction

Avoid/Use Alternative

apixaban + paroxetine

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• pentobarbital
Eliquis (apixaban)

+

pentobarbital

1 interaction

Avoid/Use Alternative

apixaban + pentobarbital

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. apixaban levels, efficacy (hepatic metab. induced)

• phenobarbital
Eliquis (apixaban)

+

phenobarbital

1 interaction

Avoid/Use Alternative

apixaban + phenobarbital

avoid combo: combo may decr. apixaban levels, efficacy (hepatic metab. induced, P-gp-mediated transport possibly induced)

• phenytoin
Eliquis (apixaban)

+

phenytoin

1 interaction

Avoid/Use Alternative

apixaban + phenytoin

avoid combo: combo may decr. apixaban levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• pibrentasvir
Eliquis (apixaban)

+

pibrentasvir

1 interaction

Avoid/Use Alternative

apixaban + pibrentasvir

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• pirtobrutinib
Eliquis (apixaban)

+

pirtobrutinib

1 interaction

Avoid/Use Alternative

apixaban + pirtobrutinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects)

• posaconazole
Eliquis (apixaban)

+

posaconazole

1 interaction

Avoid/Use Alternative

apixaban + posaconazole

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• primidone
Eliquis (apixaban)

+

primidone

1 interaction

Avoid/Use Alternative

apixaban + primidone

avoid combo: combo may decr. apixaban levels, efficacy (hepatic metab. induced, P-gp-mediated transport possibly induced)

• propafenone
Eliquis (apixaban)

+

propafenone

1 interaction

Avoid/Use Alternative

apixaban + propafenone

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• quercetin
Eliquis (apixaban)

+

quercetin

1 interaction

Avoid/Use Alternative

apixaban + quercetin

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• quinidine (antiarrhythmic)
Eliquis (apixaban)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

apixaban + quinidine (antiarrhythmic)

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• quinidine (CYP2D6 inhibitor)
Eliquis (apixaban)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

apixaban + quinidine (CYP2D6 inhibitor)

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• quinine
Eliquis (apixaban)

+

quinine

1 interaction

Avoid/Use Alternative

apixaban + quinine

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• ranolazine
Eliquis (apixaban)

+

ranolazine

1 interaction

Avoid/Use Alternative

apixaban + ranolazine

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• ribociclib
Eliquis (apixaban)

+

ribociclib

1 interaction

Avoid/Use Alternative

apixaban + ribociclib

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• rifabutin
Eliquis (apixaban)

+

rifabutin

1 interaction

Avoid/Use Alternative

apixaban + rifabutin

avoid combo: combo may decr. apixaban levels, efficacy (hepatic metab. induced, P-gp-mediated transport possibly induced)

• rifampin
Eliquis (apixaban)

+

rifampin

1 interaction

Avoid/Use Alternative

apixaban + rifampin

avoid combo: combo may decr. apixaban levels, efficacy; may incr. risk of bleeding, incl. life-threatening (hepatic metab. induced, P-gp-mediated transport induced; additive effects)

• rifapentine
Eliquis (apixaban)

+

rifapentine

1 interaction

Avoid/Use Alternative

apixaban + rifapentine

avoid combo: combo may decr. apixaban levels, efficacy (hepatic metab. induced, P-gp-mediated transport possibly induced)

• ritonavir
Eliquis (apixaban)

+

ritonavir

1 interaction

Avoid/Use Alternative

apixaban + ritonavir

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• rivaroxaban
Eliquis (apixaban)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

apixaban + rivaroxaban

use alternative or monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• rolapitant
Eliquis (apixaban)

+

rolapitant

1 interaction

Avoid/Use Alternative

apixaban + rolapitant

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• rucaparib
Eliquis (apixaban)

+

rucaparib

1 interaction

Avoid/Use Alternative

apixaban + rucaparib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• sarecycline
Eliquis (apixaban)

+

sarecycline

1 interaction

Avoid/Use Alternative

apixaban + sarecycline

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• selpercatinib
Eliquis (apixaban)

+

selpercatinib

1 interaction

Avoid/Use Alternative

apixaban + selpercatinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects)

• simvastatin
Eliquis (apixaban)

+

simvastatin

1 interaction

Avoid/Use Alternative

apixaban + simvastatin

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• sorafenib
Eliquis (apixaban)

+

sorafenib

1 interaction

Avoid/Use Alternative

apixaban + sorafenib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport possibly inhibited, additive effects)

• sotagliflozin
Eliquis (apixaban)

+

sotagliflozin

1 interaction

Avoid/Use Alternative

apixaban + sotagliflozin

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• sotorasib
Eliquis (apixaban)

+

sotorasib

1 interaction

Avoid/Use Alternative

apixaban + sotorasib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider apixaban dose adjustment or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider apixaban dose adjustment: combo may incr. or decr. apixaban levels, incr. risk of bleeding, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metab. induced)

• sparsentan
Eliquis (apixaban)

+

sparsentan

1 interaction

Avoid/Use Alternative

apixaban + sparsentan

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• St. John's wort
Eliquis (apixaban)

+

St. John's wort

1 interaction

Avoid/Use Alternative

apixaban + St. John's wort

avoid combo: combo may decr. apixaban levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• stiripentol
Eliquis (apixaban)

+

stiripentol

1 interaction

Avoid/Use Alternative

apixaban + stiripentol

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• suvorexant
Eliquis (apixaban)

+

suvorexant

1 interaction

Avoid/Use Alternative

apixaban + suvorexant

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• tacrolimus
Eliquis (apixaban)

+

tacrolimus

1 interaction

Avoid/Use Alternative

apixaban + tacrolimus

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• telmisartan
Eliquis (apixaban)

+

telmisartan

1 interaction

Avoid/Use Alternative

apixaban + telmisartan

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• temsirolimus
Eliquis (apixaban)

+

temsirolimus

1 interaction

Avoid/Use Alternative

apixaban + temsirolimus

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• tepotinib
Eliquis (apixaban)

+

tepotinib

1 interaction

Avoid/Use Alternative

apixaban + tepotinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• tezacaftor/ivacaftor
Eliquis (apixaban)

+

tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

apixaban + tezacaftor/ ivacaftor

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• ticagrelor
Eliquis (apixaban)

+

ticagrelor

1 interaction

Avoid/Use Alternative

apixaban + ticagrelor

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects)

• tipranavir
Eliquis (apixaban)

+

tipranavir

1 interaction

Avoid/Use Alternative

apixaban + tipranavir

avoid combo: combo may incr. or decr. apixaban levels, incr. risk of bleeding (incl. life-threatening), other adverse effects or decr. efficacy (hepatic metab. inhibited, P-gp-mediated transport altered, additive effects)

• tolvaptan
Eliquis (apixaban)

+

tolvaptan

1 interaction

Avoid/Use Alternative

apixaban + tolvaptan

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• trazodone
Eliquis (apixaban)

+

trazodone

1 interaction

Avoid/Use Alternative

apixaban + trazodone

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• trimethoprim
Eliquis (apixaban)

+

trimethoprim

1 interaction

Avoid/Use Alternative

apixaban + trimethoprim

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• tucatinib
Eliquis (apixaban)

+

tucatinib

1 interaction

Avoid/Use Alternative

apixaban + tucatinib

monitor bleeding s/sx; decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• turmeric
Eliquis (apixaban)

+

turmeric

1 interaction

Avoid/Use Alternative

apixaban + turmeric

avoid combo w/ oral turmeric: combo may incr. or decr. apixaban levels, incr. risk of bleeding, other adverse effects or decr. efficacy (P-gp-mediated transport altered)

• uridine triacetate
Eliquis (apixaban)

+

uridine triacetate

1 interaction

Avoid/Use Alternative

apixaban + uridine triacetate

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• valbenazine
Eliquis (apixaban)

+

valbenazine

1 interaction

Avoid/Use Alternative

apixaban + valbenazine

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• vandetanib
Eliquis (apixaban)

+

vandetanib

1 interaction

Avoid/Use Alternative

apixaban + vandetanib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited, additive effects)

• vanzacaftor/tezacaftor/deutivacaftor
Eliquis (apixaban)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Avoid/Use Alternative

apixaban + vanzacaftor/ tezacaftor/ deutivacaftor

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• velpatasvir
Eliquis (apixaban)

+

velpatasvir

1 interaction

Avoid/Use Alternative

apixaban + velpatasvir

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• vemurafenib
Eliquis (apixaban)

+

vemurafenib

1 interaction

Avoid/Use Alternative

apixaban + vemurafenib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• venetoclax
Eliquis (apixaban)

+

venetoclax

1 interaction

Avoid/Use Alternative

apixaban + venetoclax

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose; give apixaban at least 6h before venetoclax: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• vimseltinib
Eliquis (apixaban)

+

vimseltinib

1 interaction

Avoid/Use Alternative

apixaban + vimseltinib

monitor bleeding s/sx; give vimseltinib at least 4h before apixaban; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• voclosporin
Eliquis (apixaban)

+

voclosporin

1 interaction

Avoid/Use Alternative

apixaban + voclosporin

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• vorapaxar
Eliquis (apixaban)

+

vorapaxar

1 interaction

Avoid/Use Alternative

apixaban + vorapaxar

avoid combo: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• voriconazole
Eliquis (apixaban)

+

voriconazole

1 interaction

Avoid/Use Alternative

apixaban + voriconazole

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• voxilaprevir
Eliquis (apixaban)

+

voxilaprevir

1 interaction

Avoid/Use Alternative

apixaban + voxilaprevir

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• xanomeline
Eliquis (apixaban)

+

xanomeline

1 interaction

Avoid/Use Alternative

apixaban + xanomeline

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• zonisamide
Eliquis (apixaban)

+

zonisamide

1 interaction

Avoid/Use Alternative

apixaban + zonisamide

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

Monitor/Modify Tx

• acalabrutinib
Eliquis (apixaban)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

apixaban + acalabrutinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ado-trastuzumab emtansine
Eliquis (apixaban)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

apixaban + ado-trastuzumab emtansine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• aducanumab
Eliquis (apixaban)

+

aducanumab

1 interaction

Monitor/Modify Tx

apixaban + aducanumab

monitor bleeding s/sx: combo may incr. risk of intracerebral bleeding, incl. life-threatening (additive effects)

• afatinib
Eliquis (apixaban)

+

afatinib

1 interaction

Monitor/Modify Tx

apixaban + afatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• alteplase
Eliquis (apixaban)

+

alteplase

1 interaction

Monitor/Modify Tx

apixaban + alteplase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• anacaulase topical
Eliquis (apixaban)

+

anacaulase topical

1 interaction

Monitor/Modify Tx

apixaban + anacaulase topical

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• anagrelide
Eliquis (apixaban)

+

anagrelide

1 interaction

Monitor/Modify Tx

apixaban + anagrelide

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• antithrombin
Eliquis (apixaban)

+

antithrombin

1 interaction

Monitor/Modify Tx

apixaban + antithrombin

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• aprepitant
Eliquis (apixaban)

+

aprepitant

1 interaction

Monitor/Modify Tx

apixaban + aprepitant

if aprepitant 3-day regimen, monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose; aprepitant single dose-regimen OK: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• argatroban
Eliquis (apixaban)

+

argatroban

1 interaction

Monitor/Modify Tx

apixaban + argatroban

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• asparaginase
Eliquis (apixaban)

+

asparaginase

1 interaction

Monitor/Modify Tx

apixaban + asparaginase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• aspirin
Eliquis (apixaban)

+

aspirin

1 interaction

Monitor/Modify Tx

apixaban + aspirin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• avacopan
Eliquis (apixaban)

+

avacopan

1 interaction

Monitor/Modify Tx

apixaban + avacopan

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• avapritinib
Eliquis (apixaban)

+

avapritinib

1 interaction

Monitor/Modify Tx

apixaban + avapritinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• axitinib
Eliquis (apixaban)

+

axitinib

1 interaction

Monitor/Modify Tx

apixaban + axitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• berotralstat
Eliquis (apixaban)

+

berotralstat

1 interaction

Monitor/Modify Tx

apixaban + berotralstat

monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• bevacizumab
Eliquis (apixaban)

+

bevacizumab

1 interaction

Monitor/Modify Tx

apixaban + bevacizumab

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• binimetinib
Eliquis (apixaban)

+

binimetinib

1 interaction

Monitor/Modify Tx

apixaban + binimetinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• bivalirudin
Eliquis (apixaban)

+

bivalirudin

1 interaction

Monitor/Modify Tx

apixaban + bivalirudin

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• brentuximab vedotin
Eliquis (apixaban)

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

apixaban + brentuximab vedotin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• bromelain
Eliquis (apixaban)

+

bromelain

1 interaction

Monitor/Modify Tx

apixaban + bromelain

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• bromfenac ophthalmic
Eliquis (apixaban)

+

bromfenac ophthalmic

1 interaction

Monitor/Modify Tx

apixaban + bromfenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• cabazitaxel
Eliquis (apixaban)

+

cabazitaxel

1 interaction

Monitor/Modify Tx

apixaban + cabazitaxel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• cabozantinib
Eliquis (apixaban)

+

cabozantinib

1 interaction

Monitor/Modify Tx

apixaban + cabozantinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• calaspargase
Eliquis (apixaban)

+

calaspargase

1 interaction

Monitor/Modify Tx

apixaban + calaspargase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cangrelor
Eliquis (apixaban)

+

cangrelor

1 interaction

Monitor/Modify Tx

apixaban + cangrelor

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• carfilzomib
Eliquis (apixaban)

+

carfilzomib

1 interaction

Monitor/Modify Tx

apixaban + carfilzomib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• cefaclor
Eliquis (apixaban)

+

cefaclor

1 interaction

Monitor/Modify Tx

apixaban + cefaclor

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefaclor tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefadroxil
Eliquis (apixaban)

+

cefadroxil

1 interaction

Monitor/Modify Tx

apixaban + cefadroxil

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefadroxil tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefazolin
Eliquis (apixaban)

+

cefazolin

1 interaction

Monitor/Modify Tx

apixaban + cefazolin

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefazolin tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefdinir
Eliquis (apixaban)

+

cefdinir

1 interaction

Monitor/Modify Tx

apixaban + cefdinir

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefdinir tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefepime
Eliquis (apixaban)

+

cefepime

1 interaction

Monitor/Modify Tx

apixaban + cefepime

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefepime tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefixime
Eliquis (apixaban)

+

cefixime

1 interaction

Monitor/Modify Tx

apixaban + cefixime

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefixime tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefotetan
Eliquis (apixaban)

+

cefotetan

1 interaction

Monitor/Modify Tx

apixaban + cefotetan

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefotetan tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefoxitin
Eliquis (apixaban)

+

cefoxitin

1 interaction

Monitor/Modify Tx

apixaban + cefoxitin

monitor bleeding s/sx, especially w/ prolonged and/or high dose cefoxitin tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefpodoxime
Eliquis (apixaban)

+

cefpodoxime

1 interaction

Monitor/Modify Tx

apixaban + cefpodoxime

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefpodoxime tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefprozil
Eliquis (apixaban)

+

cefprozil

1 interaction

Monitor/Modify Tx

apixaban + cefprozil

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefprozil tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ceftazidime
Eliquis (apixaban)

+

ceftazidime

1 interaction

Monitor/Modify Tx

apixaban + ceftazidime

monitor bleeding s/sx, especially w/ prolonged and/or high-dose ceftazidime tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ceftriaxone
Eliquis (apixaban)

+

ceftriaxone

1 interaction

Monitor/Modify Tx

apixaban + ceftriaxone

monitor bleeding s/sx, especially w/ prolonged and/or high-dose ceftriaxone tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefuroxime axetil
Eliquis (apixaban)

+

cefuroxime axetil

1 interaction

Monitor/Modify Tx

apixaban + cefuroxime axetil

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefuroxime tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cefuroxime sodium
Eliquis (apixaban)

+

cefuroxime sodium

1 interaction

Monitor/Modify Tx

apixaban + cefuroxime sodium

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cefuroxime tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• celecoxib
Eliquis (apixaban)

+

celecoxib

1 interaction

Monitor/Modify Tx

apixaban + celecoxib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• cephalexin
Eliquis (apixaban)

+

cephalexin

1 interaction

Monitor/Modify Tx

apixaban + cephalexin

monitor bleeding s/sx, especially w/ prolonged and/or high-dose cephalexin tx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• cilostazol
Eliquis (apixaban)

+

cilostazol

1 interaction

Monitor/Modify Tx

apixaban + cilostazol

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ciprofloxacin
Eliquis (apixaban)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

apixaban + ciprofloxacin

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• citalopram
Eliquis (apixaban)

+

citalopram

1 interaction

Monitor/Modify Tx

apixaban + citalopram

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• clarithromycin
Eliquis (apixaban)

+

clarithromycin

1 interaction

Monitor/Modify Tx

apixaban + clarithromycin

monitor bleeding s/sx; no dose adjustment recommended: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• clofazimine
Eliquis (apixaban)

+

clofazimine

1 interaction

Monitor/Modify Tx

apixaban + clofazimine

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• clopidogrel
Eliquis (apixaban)

+

clopidogrel

1 interaction

Monitor/Modify Tx

apixaban + clopidogrel

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• conivaptan
Eliquis (apixaban)

+

conivaptan

1 interaction

Monitor/Modify Tx

apixaban + conivaptan

monitor bleeding s/sx; consider decr. apixaban dose during and x7 days after conivaptan tx: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• crizotinib
Eliquis (apixaban)

+

crizotinib

1 interaction

Monitor/Modify Tx

apixaban + crizotinib

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• cyclosporine
Eliquis (apixaban)

+

cyclosporine

1 interaction

Monitor/Modify Tx

apixaban + cyclosporine

monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• cysteamine
Eliquis (apixaban)

+

cysteamine

1 interaction

Monitor/Modify Tx

apixaban + cysteamine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• dabigatran
Eliquis (apixaban)

+

dabigatran

1 interaction

Monitor/Modify Tx

apixaban + dabigatran

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• dalteparin
Eliquis (apixaban)

+

dalteparin

1 interaction

Monitor/Modify Tx

apixaban + dalteparin

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• danazol
Eliquis (apixaban)

+

danazol

1 interaction

Monitor/Modify Tx

apixaban + danazol

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• darunavir
Eliquis (apixaban)

+

darunavir

1 interaction

Monitor/Modify Tx

apixaban + darunavir

monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• dasatinib
Eliquis (apixaban)

+

dasatinib

1 interaction

Monitor/Modify Tx

apixaban + dasatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• deferasirox
Eliquis (apixaban)

+

deferasirox

1 interaction

Monitor/Modify Tx

apixaban + deferasirox

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• desvenlafaxine
Eliquis (apixaban)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

apixaban + desvenlafaxine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• deuruxolitinib
Eliquis (apixaban)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

apixaban + deuruxolitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diclofenac
Eliquis (apixaban)

+

diclofenac

1 interaction

Monitor/Modify Tx

apixaban + diclofenac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diclofenac ophthalmic
Eliquis (apixaban)

+

diclofenac ophthalmic

1 interaction

Monitor/Modify Tx

apixaban + diclofenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• diclofenac topical
Eliquis (apixaban)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

apixaban + diclofenac topical

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diflunisal
Eliquis (apixaban)

+

diflunisal

1 interaction

Monitor/Modify Tx

apixaban + diflunisal

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diltiazem
Eliquis (apixaban)

+

diltiazem

1 interaction

Monitor/Modify Tx

apixaban + diltiazem

monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• dimethyl fumarate
Eliquis (apixaban)

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

apixaban + dimethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• dipyridamole
Eliquis (apixaban)

+

dipyridamole

1 interaction

Monitor/Modify Tx

apixaban + dipyridamole

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• diroximel fumarate
Eliquis (apixaban)

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

apixaban + diroximel fumarate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• donanemab
Eliquis (apixaban)

+

donanemab

1 interaction

Monitor/Modify Tx

apixaban + donanemab

monitor bleeding s/sx: combo may incr. risk of intracerebral bleeding, incl. life-threatening (additive effects)

• dronedarone
Eliquis (apixaban)

+

dronedarone

1 interaction

Monitor/Modify Tx

apixaban + dronedarone

monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• duloxetine
Eliquis (apixaban)

+

duloxetine

1 interaction

Monitor/Modify Tx

apixaban + duloxetine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• duvelisib
Eliquis (apixaban)

+

duvelisib

1 interaction

Monitor/Modify Tx

apixaban + duvelisib

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• elagolix
Eliquis (apixaban)

+

elagolix

1 interaction

Monitor/Modify Tx

apixaban + elagolix

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• epoprostenol
Eliquis (apixaban)

+

epoprostenol

1 interaction

Monitor/Modify Tx

apixaban + epoprostenol

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• eptifibatide
Eliquis (apixaban)

+

eptifibatide

1 interaction

Monitor/Modify Tx

apixaban + eptifibatide

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• erlotinib
Eliquis (apixaban)

+

erlotinib

1 interaction

Monitor/Modify Tx

apixaban + erlotinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• erythromycin
Eliquis (apixaban)

+

erythromycin

1 interaction

Monitor/Modify Tx

apixaban + erythromycin

monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• escitalopram
Eliquis (apixaban)

+

escitalopram

1 interaction

Monitor/Modify Tx

apixaban + escitalopram

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• ethanol
Eliquis (apixaban)

+

ethanol

1 interaction

Monitor/Modify Tx

apixaban + ethanol

monitor bleeding s/sx w/ orally ingested alcohol: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• etodolac
Eliquis (apixaban)

+

etodolac

1 interaction

Monitor/Modify Tx

apixaban + etodolac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• evening primrose oil
Eliquis (apixaban)

+

evening primrose oil

1 interaction

Monitor/Modify Tx

apixaban + evening primrose oil

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• fedratinib
Eliquis (apixaban)

+

fedratinib

1 interaction

Monitor/Modify Tx

apixaban + fedratinib

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• fenoprofen
Eliquis (apixaban)

+

fenoprofen

1 interaction

Monitor/Modify Tx

apixaban + fenoprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• fenugreek
Eliquis (apixaban)

+

fenugreek

1 interaction

Monitor/Modify Tx

apixaban + fenugreek

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• fluconazole
Eliquis (apixaban)

+

fluconazole

1 interaction

Monitor/Modify Tx

apixaban + fluconazole

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• fluoxetine
Eliquis (apixaban)

+

fluoxetine

1 interaction

Monitor/Modify Tx

apixaban + fluoxetine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• flurbiprofen
Eliquis (apixaban)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

apixaban + flurbiprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• flurbiprofen ophthalmic
Eliquis (apixaban)

+

flurbiprofen ophthalmic

1 interaction

Monitor/Modify Tx

apixaban + flurbiprofen ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• fosamprenavir
Eliquis (apixaban)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

apixaban + fosamprenavir

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• fruquintinib
Eliquis (apixaban)

+

fruquintinib

1 interaction

Monitor/Modify Tx

apixaban + fruquintinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• garlic
Eliquis (apixaban)

+

garlic

1 interaction

Monitor/Modify Tx

apixaban + garlic

monitor bleeding s/sx, especially w/ supplemental garlic; dietary intake OK: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• gefitinib
Eliquis (apixaban)

+

gefitinib

1 interaction

Monitor/Modify Tx

apixaban + gefitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• gemtuzumab ozogamicin
Eliquis (apixaban)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

apixaban + gemtuzumab ozogamicin

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• grapefruit
Eliquis (apixaban)

+

grapefruit

1 interaction

Monitor/Modify Tx

apixaban + grapefruit

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (GI metab. inhibited)

• heparin
Eliquis (apixaban)

+

heparin

1 interaction

Monitor/Modify Tx

apixaban + heparin

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• hydrocortisone
Eliquis (apixaban)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

apixaban + hydrocortisone

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ibuprofen
Eliquis (apixaban)

+

ibuprofen

1 interaction

Monitor/Modify Tx

apixaban + ibuprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ibuprofen lysine
Eliquis (apixaban)

+

ibuprofen lysine

1 interaction

Monitor/Modify Tx

apixaban + ibuprofen lysine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• icosapent ethyl
Eliquis (apixaban)

+

icosapent ethyl

1 interaction

Monitor/Modify Tx

apixaban + icosapent ethyl

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• iloprost inhaled
Eliquis (apixaban)

+

iloprost inhaled

1 interaction

Monitor/Modify Tx

apixaban + iloprost inhaled

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• imatinib
Eliquis (apixaban)

+

imatinib

1 interaction

Monitor/Modify Tx

apixaban + imatinib

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• isavuconazonium
Eliquis (apixaban)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

apixaban + isavuconazonium

monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• ketoprofen
Eliquis (apixaban)

+

ketoprofen

1 interaction

Monitor/Modify Tx

apixaban + ketoprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ketorolac
Eliquis (apixaban)

+

ketorolac

1 interaction

Monitor/Modify Tx

apixaban + ketorolac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ketorolac ophthalmic
Eliquis (apixaban)

+

ketorolac ophthalmic

1 interaction

Monitor/Modify Tx

apixaban + ketorolac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• lecanemab
Eliquis (apixaban)

+

lecanemab

1 interaction

Monitor/Modify Tx

apixaban + lecanemab

monitor bleeding s/sx: combo may incr. risk of intracerebral bleeding, incl. life-threatening (additive effects)

• lefamulin
Eliquis (apixaban)

+

lefamulin

1 interaction

Monitor/Modify Tx

apixaban + lefamulin

ORAL LEFAMULIN: monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose; IV lefamulin use OK: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• lenvatinib
Eliquis (apixaban)

+

lenvatinib

1 interaction

Monitor/Modify Tx

apixaban + lenvatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• letermovir
Eliquis (apixaban)

+

letermovir

1 interaction

Monitor/Modify Tx

apixaban + letermovir

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• levomilnacipran
Eliquis (apixaban)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

apixaban + levomilnacipran

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• magnesium salicylate
Eliquis (apixaban)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

apixaban + magnesium salicylate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• meclofenamate
Eliquis (apixaban)

+

meclofenamate

1 interaction

Monitor/Modify Tx

apixaban + meclofenamate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• mefenamic acid
Eliquis (apixaban)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

apixaban + mefenamic acid

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• meloxicam
Eliquis (apixaban)

+

meloxicam

1 interaction

Monitor/Modify Tx

apixaban + meloxicam

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• methotrexate
Eliquis (apixaban)

+

methotrexate

1 interaction

Monitor/Modify Tx

apixaban + methotrexate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• methyl salicylate topical
Eliquis (apixaban)

+

methyl salicylate topical

1 interaction

Monitor/Modify Tx

apixaban + methyl salicylate topical

monitor bleeding s/sx, especially if methyl salicylate topical applied over large surface area: combo may incr. risk of bleeding, incl. life-threatening (additive effects, systemic salicylate absorption occurs from topical use)

• milnacipran
Eliquis (apixaban)

+

milnacipran

1 interaction

Monitor/Modify Tx

apixaban + milnacipran

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• mitapivat
Eliquis (apixaban)

+

mitapivat

1 interaction

Monitor/Modify Tx

apixaban + mitapivat

monitor bleeding s/sx; consider decr. apixaban dose adjustment: combo may incr. or decr. apixaban levels, incr. risk of bleeding, other adverse effects or decr. efficacy (hepatic metab. induced, P-gp-mediated transport possibly inhibited)

• monomethyl fumarate
Eliquis (apixaban)

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

apixaban + monomethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• mycophenolate mofetil
Eliquis (apixaban)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

apixaban + mycophenolate mofetil

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• mycophenolic acid
Eliquis (apixaban)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

apixaban + mycophenolic acid

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nabumetone
Eliquis (apixaban)

+

nabumetone

1 interaction

Monitor/Modify Tx

apixaban + nabumetone

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nattokinase
Eliquis (apixaban)

+

nattokinase

1 interaction

Monitor/Modify Tx

apixaban + nattokinase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• nepafenac ophthalmic
Eliquis (apixaban)

+

nepafenac ophthalmic

1 interaction

Monitor/Modify Tx

apixaban + nepafenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• niacin (vitamin B3)
Eliquis (apixaban)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

apixaban + niacin (vitamin B3)

monitor platelets, prothrombin time, bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• nilotinib
Eliquis (apixaban)

+

nilotinib

1 interaction

Monitor/Modify Tx

apixaban + nilotinib

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• nintedanib
Eliquis (apixaban)

+

nintedanib

1 interaction

Monitor/Modify Tx

apixaban + nintedanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nirogacestat
Eliquis (apixaban)

+

nirogacestat

1 interaction

Monitor/Modify Tx

apixaban + nirogacestat

monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• nusinersen
Eliquis (apixaban)

+

nusinersen

1 interaction

Monitor/Modify Tx

apixaban + nusinersen

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• omega-3-acid
Eliquis (apixaban)

+

omega-3-acid

1 interaction

Monitor/Modify Tx

apixaban + omega-3-acid

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• oxaliplatin
Eliquis (apixaban)

+

oxaliplatin

1 interaction

Monitor/Modify Tx

apixaban + oxaliplatin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• oxaprozin
Eliquis (apixaban)

+

oxaprozin

1 interaction

Monitor/Modify Tx

apixaban + oxaprozin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pacritinib
Eliquis (apixaban)

+

pacritinib

1 interaction

Monitor/Modify Tx

apixaban + pacritinib

monitor platelets, bleeding s/sx; if also combined w/ moderate-strong CYP3A4 inhibitor, consider apixaban dose adjustment: combo may incr. or decr. apixaban levels, incr. risk of bleeding (incl. life-threatening), other adverse effects or decr. efficacy (hepatic metab. induced, P-gp-mediated transport inhibited, additive effects)

• pazopanib
Eliquis (apixaban)

+

pazopanib

1 interaction

Monitor/Modify Tx

apixaban + pazopanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pegaspargase
Eliquis (apixaban)

+

pegaspargase

1 interaction

Monitor/Modify Tx

apixaban + pegaspargase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• penicillin G
Eliquis (apixaban)

+

penicillin G

1 interaction

Monitor/Modify Tx

apixaban + penicillin G

monitor bleeding s/sx, especially w/ large penicillin G doses and/or concomitant renal impairment: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• pentosan polysulfate sodium
Eliquis (apixaban)

+

pentosan polysulfate sodium

1 interaction

Monitor/Modify Tx

apixaban + pentosan polysulfate sodium

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• pentoxifylline
Eliquis (apixaban)

+

pentoxifylline

1 interaction

Monitor/Modify Tx

apixaban + pentoxifylline

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• piperacillin
Eliquis (apixaban)

+

piperacillin

1 interaction

Monitor/Modify Tx

apixaban + piperacillin

monitor bleeding s/sx, especially w/ prolonged piperacillin tx and/or concomitant renal impairment: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• piroxicam
Eliquis (apixaban)

+

piroxicam

1 interaction

Monitor/Modify Tx

apixaban + piroxicam

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• plasminogen, human
Eliquis (apixaban)

+

plasminogen, human

1 interaction

Monitor/Modify Tx

apixaban + plasminogen, human

monitor bleeding s/sx, especially during and x4h after plasminogen infusion: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ponatinib
Eliquis (apixaban)

+

ponatinib

1 interaction

Monitor/Modify Tx

apixaban + ponatinib

monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban dose by 50% or avoid combo if already on 2.5 mg bid; if also combined w/ moderate CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport possibly inhibited, additive effects)

• porfimer
Eliquis (apixaban)

+

porfimer

1 interaction

Monitor/Modify Tx

apixaban + porfimer

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pralsetinib
Eliquis (apixaban)

+

pralsetinib

1 interaction

Monitor/Modify Tx

apixaban + pralsetinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• prasugrel
Eliquis (apixaban)

+

prasugrel

1 interaction

Monitor/Modify Tx

apixaban + prasugrel

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• pretomanid
Eliquis (apixaban)

+

pretomanid

1 interaction

Monitor/Modify Tx

apixaban + pretomanid

monitor bleeding s/sx: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• ramucirumab
Eliquis (apixaban)

+

ramucirumab

1 interaction

Monitor/Modify Tx

apixaban + ramucirumab

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ranibizumab
Eliquis (apixaban)

+

ranibizumab

1 interaction

Monitor/Modify Tx

apixaban + ranibizumab

monitor bleeding s/sx; consider holding apixaban prior to implant insertion: combo may incr. risk of ocular hemorrhage (additive effects)

• regorafenib
Eliquis (apixaban)

+

regorafenib

1 interaction

Monitor/Modify Tx

apixaban + regorafenib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• resveratrol
Eliquis (apixaban)

+

resveratrol

1 interaction

Monitor/Modify Tx

apixaban + resveratrol

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• reteplase
Eliquis (apixaban)

+

reteplase

1 interaction

Monitor/Modify Tx

apixaban + reteplase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• salsalate
Eliquis (apixaban)

+

salsalate

1 interaction

Monitor/Modify Tx

apixaban + salsalate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• saw palmetto
Eliquis (apixaban)

+

saw palmetto

1 interaction

Monitor/Modify Tx

apixaban + saw palmetto

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• selumetinib
Eliquis (apixaban)

+

selumetinib

1 interaction

Monitor/Modify Tx

apixaban + selumetinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet and anticoagulant effects augmented by vitamin E content in selumetinib capsules)

• sertraline
Eliquis (apixaban)

+

sertraline

1 interaction

Monitor/Modify Tx

apixaban + sertraline

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• sirolimus albumin-bound
Eliquis (apixaban)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

apixaban + sirolimus albumin-bound

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• sotatercept
Eliquis (apixaban)

+

sotatercept

1 interaction

Monitor/Modify Tx

apixaban + sotatercept

monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, incl. severe or life-threatening (additive effects)

• sugammadex
Eliquis (apixaban)

+

sugammadex

1 interaction

Monitor/Modify Tx

apixaban + sugammadex

monitor bleeding s/sx, especially w/ sugammadex 16 mg/kg: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• sulindac
Eliquis (apixaban)

+

sulindac

1 interaction

Monitor/Modify Tx

apixaban + sulindac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sunitinib
Eliquis (apixaban)

+

sunitinib

1 interaction

Monitor/Modify Tx

apixaban + sunitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tenecteplase
Eliquis (apixaban)

+

tenecteplase

1 interaction

Monitor/Modify Tx

apixaban + tenecteplase

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, duplicate tx)

• testosterone
Eliquis (apixaban)

+

testosterone

1 interaction

Monitor/Modify Tx

apixaban + testosterone

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• tirofiban
Eliquis (apixaban)

+

tirofiban

1 interaction

Monitor/Modify Tx

apixaban + tirofiban

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• tisotumab vedotin
Eliquis (apixaban)

+

tisotumab vedotin

1 interaction

Monitor/Modify Tx

apixaban + tisotumab vedotin

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• tivozanib
Eliquis (apixaban)

+

tivozanib

1 interaction

Monitor/Modify Tx

apixaban + tivozanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tolmetin
Eliquis (apixaban)

+

tolmetin

1 interaction

Monitor/Modify Tx

apixaban + tolmetin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tovorafenib
Eliquis (apixaban)

+

tovorafenib

1 interaction

Monitor/Modify Tx

apixaban + tovorafenib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• trametinib
Eliquis (apixaban)

+

trametinib

1 interaction

Monitor/Modify Tx

apixaban + trametinib

monitor bleeding s/sx, especially w/ concomitant dabrafenib use: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• treprostinil
Eliquis (apixaban)

+

treprostinil

1 interaction

Monitor/Modify Tx

apixaban + treprostinil

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• upadacitinib
Eliquis (apixaban)

+

upadacitinib

1 interaction

Monitor/Modify Tx

apixaban + upadacitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• vadadustat
Eliquis (apixaban)

+

vadadustat

1 interaction

Monitor/Modify Tx

apixaban + vadadustat

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• valproic acid
Eliquis (apixaban)

+

valproic acid

1 interaction

Monitor/Modify Tx

apixaban + valproic acid

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• venlafaxine
Eliquis (apixaban)

+

venlafaxine

1 interaction

Monitor/Modify Tx

apixaban + venlafaxine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• verapamil
Eliquis (apixaban)

+

verapamil

1 interaction

Monitor/Modify Tx

apixaban + verapamil

monitor bleeding s/sx; consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• vilazodone
Eliquis (apixaban)

+

vilazodone

1 interaction

Monitor/Modify Tx

apixaban + vilazodone

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• vinpocetine
Eliquis (apixaban)

+

vinpocetine

1 interaction

Monitor/Modify Tx

apixaban + vinpocetine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• vortioxetine
Eliquis (apixaban)

+

vortioxetine

1 interaction

Monitor/Modify Tx

apixaban + vortioxetine

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• warfarin
Eliquis (apixaban)

+

warfarin

1 interaction

Monitor/Modify Tx

apixaban + warfarin

monitor INR, bleeding s/sx; see Dosing section for switching anticoagulants: combo may incr. risk of bleeding, incl. life-threatening (synergistic effects, duplicate tx)

• willow bark
Eliquis (apixaban)

+

willow bark

1 interaction

Monitor/Modify Tx

apixaban + willow bark

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, willow bark may contain salicylates)

• zanubrutinib
Eliquis (apixaban)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

apixaban + zanubrutinib

monitor bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (additive effects)

• ziv-aflibercept
Eliquis (apixaban)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

apixaban + ziv-aflibercept

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)